Quality of Life 5 Years Following Transfemoral TAVR or SAVR in Intermediate Risk Patients.
Kleiman NS, Van Mieghem NM, Reardon MJ, Gada H, Mumtaz M, Olsen PS, Heiser J, Merhi W, Chetcuti S, Deeb GM, Chawla A, Kiaii B, Teefy P, Chu MWA, Yakubov SJ, Windecker S, Althouse AD, Baron SJ.
Kleiman NS, et al. Among authors: baron sj.
JACC Cardiovasc Interv. 2024 Apr 22;17(8):979-988. doi: 10.1016/j.jcin.2024.02.014.
JACC Cardiovasc Interv. 2024.
PMID: 38658126
Clinical Trial.